Skip to content

Alnylam Pharmaceuticals

US · ALNY #627 by market cap Listed 1970
143.82 -4.00 -2.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Founded
2002
CEO
Dr. Yvonne L Greenstreet, MB.Ch.B.
Employees
2,500
Headquarters
Cambridge, Massachusetts, United States of America
Fiscal year end
12-31
Website
alnylam.com

Company profile

Exchange
US
Symbol
ALNY
Market-cap rank
#627
Listing date
1970-01-01
Market cap
19.26B
Float cap
19.22B
Shares out
133.94M
Float shares
133.64M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Alnylam Pharmaceuticals discussion 0 comments

Add a comment